Evolus, Inc. Common Stock
$7.86
-$0.13 (-1.69%)
$7.77Day Range$8.11
Key Statistics
Market Cap
$527.74M
Shares Outstanding
66.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Feb 8, 2018
Round Lot
100
Locale
US
Trading Data
Day Open
$8.05
Day High
$8.11
Day Low
$7.77
Volume
544.1K
VWAP
$7.95
Prev Close
$7.99
Transactions
--
Acc. Volume
--
About Evolus, Inc. Common Stock
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
PHARMACEUTICAL PREPARATIONSSIC 2834353 employees520 NEWPORT CENTER DRIVE, NEWPORT BEACH, CA, 92660(949) 284-4555IPO Feb 8, 2018US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001570562
- Composite FIGI
- BBG005CX4HK8
- Share Class FIGI
- BBG005CX4HL7
- Ticker Root
- EOLS
- SIC Code
- 2834
About Evolus, Inc. Common Stock (EOLS) Stock
Evolus, Inc. Common Stock (EOLS) closed the 2026-09-17 session at $7.86, down 1.69% versus the previous close (-0.13). The stock opened at $8.05 and traded between $7.77 and $8.11 during that session. Session trading volume was 544K shares. The volume-weighted average price (VWAP) is $7.95.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
Evolus, Inc. Common Stock has a market capitalization of $527.7 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. EOLS is listed on the XNAS exchange. The company employs approximately 353 people. Evolus, Inc. Common Stock is headquartered in NEWPORT BEACH, CA. The recorded listing date is 2018-02-08.
On this page you can find market EOLS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.